Avenue therapeutics, inc. ATXI.US Overview
ATXI AI Analysis & Strategy
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
ATXI Current Performance
-
Avenue therapeutics, inc.
-1.01%
Avg of Sector
-0.79%
S&P500
ATXI Key Information
ATXI Financial Forecast
Unit : USD
ATXI Earnings Table
ATXI Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Price of ATXI
ATXI FAQ
When is ATXI's latest earnings report released?
The most recent financial report for Avenue therapeutics, inc. (ATXI) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ATXI’s short-term business performance and financial health. For the latest updates on ATXI’s earnings releases, visit this page regularly.
How much cash does ATXI have?
At the end of the period, Avenue therapeutics, inc. (ATXI) held Total Cash and Cash Equivalents of 3.5M, accounting for 0.97 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is ATXI's EPS continuing to grow?
According to the past four quarterly reports, Avenue therapeutics, inc. (ATXI)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.62. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ATXI?
Avenue therapeutics, inc. (ATXI)’s Free Cash Flow (FCF) for the period is -1.19M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 61.99% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.